Clinical Trials e-Newsletter | June 2022
Unleash the Power of Your Own Immune System to Battle Prostate Cancer 
Immuno-Oncology (IO) also known as cancer immunotherapy is a form of cancer treatment that uses and enhances the power of the cancer patient’s own immune system to slow the growth or kill the cancer cells. This form of cancer treatment educates an individual’s immune system and/or increases the available numbers of immune cells to fight cancer. 
There are a variety of cancer IO-based therapies such as targeted antibodies, adoptive cell therapies, checkpoint inhibitors, cytokines, and even vaccines. Many of these therapies can also be used in combination with radiation, chemotherapy, and surgery to enhance their effectiveness. In this newsletter, we will discuss two types of IO therapies, which are engineered to increase cancer killing efficiency. The first is Chimeric Antigen Receptor (CAR) T-cell therapy and a second is Bi-specific T-cell engager antibodies (BiTEs).

CAR T-cell therapy involves collecting the patient’s own immune cells, increasing the immune cell number in the laboratory, and modifying it so it specifically attacks the prostate cancer cell. These modified immune cells are re-introduced into the patient where they seek-out and eliminate cancerous cells.
BiTEs are targeted antibodies which are designed to bind a molecule found on the surface of a type of immune cell (i.e., T-cell) and a molecule found on the surface of the cancer. This bi-specific function serves to concentrate T-cells on the cancer site like a “swarm of killer bees”. By concentrating these T-cells, the cancer growth slows or stops. 

Increasing numbers of clinical trials incorporate IO therapies. To learn more about clinical trials using these IO therapies for advanced prostate cancer, please review the trials below.
  • AMG 340This clinical trial is for men with metastatic castration-resistant prostate cancer (mCRPC) who have received two or more other forms of therapy.

  • P-PMSA-101: This clinical trial is for patients with mCRPC, which has worsened despite having received hormonal and chemotherapeutic treatments.
Learn more about Immuno-Oncology
Register Now for Webinar

Tuesday June 28th, 2022
6:00pm EST
For more clinical trials information visit:
PHEN Clinical Trial Sponsors